App, Smart Band and Education for People with COPD
Tests an app, smart band and health education in adults with COPD.
Plain-language title generated from the registry record
Registry title: Effect of an App-based Intervention on Air Pollution in COPD Patients
Key facts
- Where
- Salamanca, SpainSee the site
Where in Spain
- Unidad de Investigación de AP de SalamancaSalamanca, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundacion para la Investigacion y Formacion en Ciencias de la Salud
- Trial code
- NCT07074093
- Record updated
- 20 July 2025
- Original description
This study will test whether a combination of health education, a mobile app, and a smart band can help people with chronic obstructive pulmonary disease (COPD) improve their quality of life and reduce flare-ups.Read full original descriptionShow less
Effect of an Educational Intervention and an App-based Outdoor Air Pollution Alert System on Reducing Exacerbations in COPD Patients
This study will test whether a combination of health education, a mobile app, and a smart band can help people with chronic obstructive pulmonary disease (COPD) improve their quality of life and reduce flare-ups.
Participants will be randomly assigned to one of two groups:
One group will receive health education, use a mobile app that shows real-time air quality (AirVisual), and wear a smart band that tracks activity and sleep (Amazfit Band 5).
The other group will receive standard care and advice.
All participants will complete health checks and quality-of-life questionnaires at the beginning of the study and again after 6 months.
The goal is to find out if this combination of tools helps people with COPD manage their condition better and have fewer flare-ups.
Inclusion: Male or female, aged 18 years or older; Clinical diagnosis of chronic obstructive pulmonary disease (COPD) based on GOLD 2022 criteria (post-bronchodilator FEV1/FVC < 0.70); Receiving care at urban primary care centers in Salamanca, Spain; Able to use a smartphone (independently or with minimal assistance); Able and willing to provide written informed consent.
Exclusion: Diagnosis of a respiratory disease other than COPD (e.g., asthma, interstitial lung disease); Moderate to severe cognitive impairment; Significant physical limitation that prevents participation in physical activity (e.g., NYHA Class III or IV heart failure, musculoskeletal conditions limiting walking); Advanced kidney or liver disease; Severe mental illness or terminal condition; Participation in another clinical trial; Inability to use the mobile phone or smart band due to physical or technological limitations; Plans to relocate to another city within 12 months of study start.